Tumor Endothelial Cell—A Biological Tool for Translational Cancer Research
Open Access
- 2 May 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9), 3238
- https://doi.org/10.3390/ijms21093238
Abstract
Going from bench to bedside is a simplified description of translational research, with the ultimate goal being to improve the health status of mankind. Tumor endothelial cells (TECs) perform angiogenesis to support the growth, establishment, and dissemination of tumors to distant organs. TECs have various features that distinguish them from normal endothelial cells, which include alterations in gene expression patterns, higher angiogenic and metabolic activities, and drug resistance tendencies. The special characteristics of TECs enhance the vulnerability of tumor blood vessels toward antiangiogenic therapeutic strategies. Therefore, apart from being a viable therapeutic target, TECs would act as a better mediator between the bench (i.e., angiogenesis research) and the bedside (i.e., clinical application of drugs discovered through research). Exploitation of TEC characteristics could reveal unidentified strategies of enhancing and monitoring antiangiogenic therapy in the treatment of cancer, which are discussed in this review.Keywords
This publication has 145 references indexed in Scilit:
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cellsBritish Journal of Cancer, 2012
- Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progressionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Judah Folkman, a pioneer in the study of angiogenesisAngiogenesis, 2008
- Genes that Distinguish Physiological and Pathological AngiogenesisCancer Cell, 2007
- Angiogenesis in life, disease and medicineNature, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996